Weight loss pills — good or bad? It is a question many people ask, yet the answer depends heavily on which product is being considered and how it is used. Licensed weight loss medications, when prescribed appropriately under medical supervision and alongside structured lifestyle changes, can offer meaningful clinical benefits for eligible adults living with obesity. However, unregulated products purchased online carry serious risks. This article explains how approved UK weight loss medications work, what the clinical evidence shows, what side effects to expect, and when to speak to a GP or pharmacist about your options.

How Weight Loss Pills Work and Who They Are Intended For

Weight loss pills work via mechanisms including appetite suppression, fat absorption inhibition, or gut hormone mimicry, and are indicated for adults with a BMI of 28–30 kg/m² or above, as an adjunct to lifestyle intervention rather than a standalone treatment.

Weight loss medications, often referred to colloquially as 'weight loss pills', are pharmacological agents designed to support weight reduction in individuals for whom lifestyle interventions alone have proven insufficient. They are not intended as a first-line or standalone solution, but rather as an adjunct to a structured programme involving dietary changes, increased physical activity, and behavioural support.

These medications work through several distinct mechanisms depending on their class. Some act centrally on the brain to suppress appetite by modulating neurotransmitters involved in hunger and satiety. Others work peripherally — for example, by inhibiting the absorption of dietary fat in the gastrointestinal tract, or by mimicking gut hormones that regulate insulin secretion and appetite signalling.

Eligibility thresholds differ between individual medicines and are defined by their UK Summary of Product Characteristics (SmPC) and NICE guidance. As a general guide:

• Orlistat is licensed for adults with a BMI of 28 kg/m² or above (prescription-strength Xenical) or 28 kg/m² or above (over-the-counter Alli at the lower 60 mg dose).

• Injectable GLP-1 and dual GIP/GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea. However, NICE access criteria for these agents within NHS specialist services are narrower — see the NICE and NHS Guidance section below.

All of these medicines are indicated for adults only; over-the-counter orlistat (Alli) is restricted to those aged 18 and over.

Contraindications and precautions vary by agent and are detailed in each medicine's SmPC. As examples: orlistat is contraindicated in chronic malabsorption syndromes and cholestasis; GLP-1 and GIP/GLP-1 receptor agonists are contraindicated in pregnancy and in individuals with known hypersensitivity to the active substance. None of the currently licensed UK anti-obesity medicines carry a blanket contraindication based on cardiovascular history alone, though individual cardiovascular circumstances must always be assessed by a clinician.

Because injectable agents are typically initiated only within specialist (Tier 3 or Tier 4) weight management services under NICE, eligibility is always assessed on an individual basis by a qualified healthcare professional. Reproductive safety is an important consideration: all weight loss medications should be avoided during pregnancy and breastfeeding. Women of childbearing potential should use effective contraception whilst taking these medicines. For semaglutide (Wegovy) specifically, the SmPC advises stopping treatment at least two months before a planned pregnancy, owing to the drug's prolonged half-life.

Self-prescribing or purchasing unregulated products online carries significant risks and should be avoided.

Types of Weight Loss Medication Available in the UK

UK-licensed options include orlistat (Xenical/Alli), semaglutide 2.4 mg (Wegovy), tirzepatide (Mounjaro), liraglutide 3 mg (Saxenda), and naltrexone/bupropion (Mysimba), each with a distinct mechanism, licensing status, and NHS availability.

Several weight loss medications are currently licensed and available in the UK, each with a distinct pharmacological profile. Understanding the differences between them helps patients and clinicians make informed, evidence-based decisions.

Orlistat (prescription-strength brand name Xenical 120 mg; also available over the counter as Alli 60 mg) is the longest-established option. It works by inhibiting pancreatic and gastric lipases, thereby reducing the absorption of dietary fat by approximately 30%. It is taken with each main meal and requires adherence to a low-fat diet to minimise gastrointestinal side effects. Alli is available without prescription to adults aged 18 and over with a BMI of 28 kg/m² or above, for a maximum of six months of continuous OTC use, after pharmacist assessment.

Experiencing these side effects? Our pharmacists can help you navigate them →

Semaglutide 2.4 mg (Wegovy) is a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a once-weekly subcutaneous injection. It is licensed by the MHRA specifically for chronic weight management in adults and works by slowing gastric emptying, reducing appetite, and enhancing feelings of fullness. It should not be confused with semaglutide 0.5 mg or 1 mg (Ozempic), which is a separate product licensed for the treatment of type 2 diabetes and is not licensed for weight management. A related GLP-1 receptor agonist, liraglutide 3 mg (Saxenda), operates via the same mechanism but is administered as a daily injection; it holds a UK licence for weight management but is not routinely commissioned by the NHS for general obesity management.

Tirzepatide (Mounjaro) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that has received MHRA approval for weight management in adults. It is administered as a once-weekly subcutaneous injection and has demonstrated substantial weight reduction in clinical trials. Its UK SmPC confirms the weight management indication and dosing schedule.

Naltrexone/bupropion (Mysimba) holds a Great Britain marketing authorisation as an adjunct to a reduced-calorie diet and increased physical activity in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with weight-related comorbidities. However, it is not routinely commissioned by the NHS and is not currently recommended by NICE for standard obesity management pathways.

It is worth noting that some medications used 'off-label' for weight loss — such as certain antidepressants or stimulants — are not licensed for this purpose in the UK and should not be used without specialist oversight. Equally, many products marketed online as 'weight loss pills' are unregulated and may contain undisclosed or harmful ingredients. Always use UK brand names and verify that any product is obtained through a regulated, legitimate channel.

Potential Benefits Supported by Clinical Evidence

Clinical trials demonstrate meaningful benefits beyond weight reduction, including reduced cardiovascular events with semaglutide (SELECT trial) and improved glycaemic control, blood pressure, and quality of life across licensed agents.

When used appropriately and under medical supervision, licensed weight loss medications can offer meaningful clinical benefits beyond simple reduction in body weight. The evidence base for several of these agents is now substantial, drawn from large-scale randomised controlled trials.

Orlistat has been shown in the XENDOS study (Diabetes Care, 2004) to produce weight loss of approximately 3–4 kg more than placebo over one year when combined with lifestyle modification. Importantly, that trial also demonstrated a significant reduction in the progression from impaired glucose tolerance to type 2 diabetes over four years.

The STEP 1 trial (New England Journal of Medicine, 2021) provided compelling evidence for semaglutide 2.4 mg (Wegovy), with participants achieving an average weight loss of around 15% of body weight over 68 weeks compared with approximately 2.4% in the placebo group. Participants also showed improvements in cardiovascular risk factors, blood pressure, and glycaemic control. More recently, the SELECT trial (New England Journal of Medicine, 2023) demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, providing evidence of benefit beyond weight reduction alone.

Tirzepatide has demonstrated even greater efficacy in the SURMOUNT-1 trial (New England Journal of Medicine, 2022), with participants losing up to 20–22% of body weight on the highest dose, alongside significant improvements in metabolic markers. These findings contributed to its MHRA approval for weight management.

Beyond weight reduction itself, the broader benefits of these medications may include:

• Improved glycaemic control and reduced risk of type 2 diabetes

• Lower blood pressure and cholesterol levels

• Reduced joint load and improved mobility

• Enhanced quality of life and psychological wellbeing

It is important to note that outcomes vary according to dose, adherence, and the intensity of the accompanying lifestyle programme. Direct head-to-head comparisons between agents are limited, so apparent differences in efficacy should be interpreted with caution. Benefits are typically sustained only whilst the medication is continued, and weight regain is common upon cessation without ongoing lifestyle support.

Risks, Side Effects and Safety Concerns to Be Aware Of

Orlistat commonly causes gastrointestinal side effects, while GLP-1 and GIP/GLP-1 receptor agonists carry risks of pancreatitis, gallbladder disease, and acute kidney injury; unregulated online products pose additional serious safety hazards.

As with all pharmacological treatments, weight loss medications carry a risk of side effects, and these must be carefully weighed against the potential benefits on an individual basis. The nature and severity of adverse effects vary considerably between drug classes.

Orlistat most commonly causes gastrointestinal side effects, particularly when dietary fat intake is not adequately reduced. These include:

• Oily or fatty stools (steatorrhoea)

• Faecal urgency or incontinence

• Flatulence and abdominal discomfort

These effects, while unpleasant, are generally not dangerous and often serve as a behavioural deterrent to high-fat food consumption. Orlistat can also reduce the absorption of fat-soluble vitamins (A, D, E, and K); a multivitamin supplement taken at bedtime (separated from orlistat doses) is advisable during treatment. Rare but serious harms include severe hepatic injury and oxalate nephropathy, which have been reported in post-marketing surveillance.

Orlistat has important contraindications and drug interactions that must be assessed before use. It is contraindicated in chronic malabsorption syndromes and cholestasis. Key interactions include: ciclosporin (contraindicated — orlistat reduces ciclosporin absorption significantly); warfarin and other anticoagulants (INR should be monitored closely); and levothyroxine (administer at least four hours apart from orlistat to avoid reduced absorption).

Worried about interactions with other medications? Speak to one of our pharmacists →

GLP-1 receptor agonists (semaglutide, liraglutide) and the dual GIP/GLP-1 receptor agonist (tirzepatide) are most commonly associated with nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation. These effects tend to diminish over time and can often be mitigated by slow dose titration and dietary adjustments. More serious adverse effects and precautions include:

• Pancreatitis: cases have been reported; patients should be advised to seek urgent medical attention if they develop severe, persistent abdominal pain radiating to the back.

• Gallbladder disease: cholelithiasis and cholecystitis have been reported; seek urgent care for right upper quadrant pain, fever, or jaundice.

• Acute kidney injury: usually secondary to dehydration from gastrointestinal side effects; ensure adequate fluid intake.

• Diabetic retinopathy: worsening has been observed in patients with type 2 diabetes treated with semaglutide; ophthalmological monitoring may be appropriate in those with pre-existing retinopathy.

• Hypoglycaemia: risk is increased when used concomitantly with insulin or sulphonylureas; dose adjustment of those agents may be required.

• Peri-operative considerations: delayed gastric emptying may increase the risk of pulmonary aspiration during anaesthesia; patients should inform their surgical and anaesthetic teams.

Regarding thyroid safety: animal studies with GLP-1 receptor agonists identified a signal for thyroid C-cell tumours, but this has not been confirmed in humans. In the UK and EU, the SmPCs for these agents list a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) as a precaution (not a formal contraindication); clinicians should discuss the theoretical risk with patients who have such a history before prescribing.

A broader safety concern relates to the unregulated market for weight loss products. Many pills sold online or in unlicensed outlets contain stimulants, diuretics, laxatives, or undisclosed pharmaceutical agents. These products have been linked to serious adverse events including cardiac arrhythmias, liver damage, and death. The MHRA regularly issues warnings about such products, and patients are strongly advised to use only medications obtained through legitimate, regulated channels.

Patients and carers are encouraged to report any suspected side effects from licensed medicines to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

NICE and NHS Guidance on Prescribing Weight Loss Medication

NICE recommends orlistat within standard NHS pathways and newer injectable agents only within specialist weight management services, with agent-specific continuation rules requiring at least 5% body weight loss within defined timeframes.

In the UK, the prescribing of weight loss medication is guided primarily by the National Institute for Health and Care Excellence (NICE), whose recommendations form the basis of NHS clinical practice. NICE guidance ensures that treatments are used appropriately, cost-effectively, and in line with the best available evidence.

NICE clinical guideline CG189 (Obesity: identification, assessment and management) recommends that drug treatment should only be considered after dietary, exercise, and behavioural approaches have been initiated and evaluated. Orlistat remains the only oral medication recommended within standard NHS prescribing pathways for obesity and should be prescribed as part of an overall weight management plan. The continuation rule for orlistat under CG189 is that treatment should be reviewed after 12 weeks: if the patient has not lost at least 5% of their initial body weight, orlistat should normally be discontinued.

For liraglutide 3 mg (Saxenda), the SmPC continuation criterion is that treatment should be discontinued if the patient has not lost at least 5% of initial body weight after 16 weeks at the maintenance dose.

For newer injectable agents, NICE has issued specific technology appraisals:

• Semaglutide 2.4 mg (Wegovy) was recommended by NICE in 2023 for use within specialist weight management services for adults with a BMI of 35 kg/m² or above and at least one weight-related comorbidity, or in certain lower BMI groups where clinically appropriate per the appraisal criteria. Treatment is recommended for a maximum of two years. The continuation criterion is that the patient should have lost at least 5% of initial body weight after 12 weeks at the maintenance dose; if not, treatment should be stopped.

• Tirzepatide (Mounjaro) received a positive NICE recommendation in 2024 under similar specialist service criteria. Patients and clinicians should refer to the published NICE technology appraisal for the precise BMI thresholds, comorbidity requirements, and continuation rules applicable at the time of prescribing.

Key principles underpinning NICE guidance include:

• Medication should complement, not replace, lifestyle intervention

• Treatment should be reviewed regularly to assess efficacy and tolerability, with agent-specific stop rules applied

• Injectable agents should be prescribed within a structured specialist (Tier 3 or Tier 4) weight management programme with dietary and behavioural support

• Prescribing decisions should be made by, or in consultation with, a clinician experienced in obesity management

NHS availability of these newer medications remains subject to local integrated care board (ICB) commissioning decisions and specialist referral pathways, meaning access may vary across different regions of England, Scotland, Wales, and Northern Ireland. Patients should discuss referral options with their GP.

When to Speak to a GP or Pharmacist About Your Options

Speak to your GP if your BMI meets prescribing thresholds or weight-related comorbidities are present; consult a pharmacist for OTC orlistat suitability; seek urgent care for severe abdominal pain, jaundice, chest pain, or signs of allergic reaction.

Deciding whether weight loss medication is appropriate is a decision that should always involve a qualified healthcare professional. Self-medicating with unregulated or prescription-only products obtained without medical oversight is unsafe and potentially harmful. If you are considering weight loss medication, your GP or pharmacist is the right starting point.

You should speak to your GP if:

• Your BMI is 30 kg/m² or above, or 27 kg/m² or above with a weight-related health condition such as type 2 diabetes, hypertension, or sleep apnoea

• You have made sustained efforts to lose weight through diet and exercise without sufficient success

• You have a condition that may be improved by weight reduction

• You are experiencing side effects from a weight loss medication you have already been prescribed

Your GP can also refer eligible patients to Tier 3 or Tier 4 specialist weight management services, where assessment for injectable treatments such as semaglutide (Wegovy) or tirzepatide (Mounjaro) takes place in line with NICE criteria. Before starting any weight loss medication, a clinician will typically carry out baseline assessments including pregnancy status, HbA1c, renal function, lipid profile, blood pressure, and a full medicines review — including discussion of contraception and pregnancy plans for women of childbearing potential.

You should speak to a pharmacist if:

• You are considering over-the-counter orlistat (Alli) and want guidance on suitability (BMI 28 kg/m² or above, aged 18 or over) and safe use

• You have questions about interactions between weight loss products and existing medications

• You have purchased a product online and are unsure whether it is safe or legitimate

Pharmacists can assess your suitability for OTC orlistat, screen for interactions (including with ciclosporin, warfarin, and levothyroxine), and advise on safe use including dietary guidance and vitamin supplementation.

Seek urgent medical attention — or call 999 — if you experience any of the following whilst taking any weight loss medication:

• Severe abdominal pain, particularly pain radiating to the back (possible pancreatitis)

• Persistent vomiting, right upper quadrant pain, fever, or jaundice (possible gallbladder disease)

• Chest pain or palpitations

• Swelling of the face, lips, tongue, or throat, or difficulty breathing (possible severe allergic reaction — call 999 immediately)

• Signs of significant dehydration

Ultimately, the question of whether weight loss pills are 'good or bad' does not have a simple answer. Licensed medications, used appropriately under medical supervision and as part of a structured programme, can be a valuable and evidence-based tool for individuals living with obesity. However, they are not a universal solution, and their benefits must always be considered alongside individual health circumstances, potential risks, and a commitment to long-term lifestyle change.

Frequently Asked Questions